MS On the Move Luncheon

May 24, 2017

I had the pleasure of attending the North Florida MS Society’s On Move Luncheon last week.  I have long had a close relationship with the North Florida MS Society due to my personal connection with MS (several family members and many friends are currently living with MS).  I am always happy to support their efforts in the community.  The MS Society is the largest funder of private research in drugs that slow the progression of the disease and ease the symptoms.


The good news is that the FDA approved the first drug–Ocrevus–to treat to treat primary progressive MS (PPMS).  There are already several treatments for the common form, relapsing-remitting MS (RRMS), which affects about 85% of MS patients. But the FDA gave Ocrevus a “breakthrough therapy designation” last year because it also treats PPMS, an especially debilitating form of MS where the disease steadily worsens rather than having periods of relapse or remission. The CDC estimates about 15% of patients with MS have PPMS.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: